

Company Overview

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immunology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immunology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development

Nov 14 2018, 4:00 AM EST

BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update

Nov 9 2018, 7:00 AM EST

BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer

Nov 5 2018, 4:00 AM EST

Stock Overview

Symbol	BTAI
Exchange	Nasdaq
Market Cap	82.76m
Last Price	\$5.29
52-Week	\$5.00 - \$14.7899

11/14/2018 04:00 PM EST

Investor Relations

Lee Roth
T: 646-536-7012
lroth@theruthgroup.com

Management Team

Vimal Mehta, Ph.D.

Chief Executive Officer & Founder

Frank D. Yocca, Ph.D.

Chief Scientific Officer

Vincent J.O'Neill M.D.

Senior Vice President & Chief Medical Officer

Richard I. Steinhart

Vice President & Chief Financial Officer

Chids Mahadevan

Vice President, Finance & Chief Accounting Officer

Chetan D. Lathia, Ph.D.

Senior Vice President & Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

Cedric Burg, Ph.D.

VP, Head of Global Clinical Operations and Project Management

Vikas Sharma, Ph.D.

Vice President of Business Development

Michael De Vivo Ph.D.

Vice President, Neuroscience

David C. Hanley

Vice President and Head of Global Pharmaceutical Development and Operations

BioXcel Therapeutics, Inc.

555 Long Wharf Drive
5th Floor
New Haven, CT 06511
United States

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.